Steven Cashman serves as Chief Business Officer at Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company revolutionizing medical imaging with its handheld, whole-body ultrasound technology. With over 25 years of experience in the healthcare and medical device industries, Cashman has built a distinguished career focused on ultrasound innovation, commercial strategy, and global market expansion. He joined Butterfly in 2021, bringing deep expertise from his tenure at GE Healthcare, where he spent more than two decades in senior leadership roles, including Global Leader for Interventional Ultrasound and President of Advanced Visualization. His time at GE honed his skills in driving product commercialization, forging strategic partnerships, and scaling ultrasound solutions across clinical settings worldwide. Prior to GE, Cashman held progressive roles at leading medtech firms, culminating in his position as President and CEO of Pristine Surgical, where he spearheaded the development and market entry of advanced surgical guidance systems. Among his notable achievements are accelerating revenue growth for GE's ultrasound portfolio by over 50% in key segments, launching groundbreaking imaging technologies adopted in over 100 countries, and securing multimillion-dollar partnerships that expanded access to point-of-care diagnostics. Cashman's strategic vision has consistently bridged innovation with practical deployment, earning him recognition as a thought leader in interventional imaging. At Butterfly Network, Cashman leads the company's business development, commercial operations, and strategic alliances, playing a pivotal role in scaling the Butterfly iQ+ platform to empower clinicians with affordable, AI-powered ultrasound anywhere. Under his guidance, Butterfly has forged key collaborations with health systems, governments, and tech giants, driving adoption in emergency medicine, primary care, and global health initiatives. His efforts have positioned Butterfly as a leader in democratizing ultrasound, with a focus on sustainable growth and expanding the company's impact on patient outcomes worldwide.